Tag: acquisition

Mergers and Acquisitions

Novo Nordisk acquires Embark Biotech in deal worth over €470m

August 31, 2023


The transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting obesity and other cardiometabolic diseases. In exchange, Embark Biotech will receive an upfront cash payment of €15m and will also be eligible to […]

Mergers and Acquisitions

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

January 9, 2023

Via: Pharmaphorum

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]

Industry, Mergers and Acquisitions, Pharma

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

December 28, 2022

Via: Pharmaphorum

In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma […]

Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Gilead buys into multiple myeloma cell therapy with Arcellx deal

December 9, 2022

Via: Biopharma Dive

Gilead placed a major bet on cell therapy with its $12 billion acquisition of Kite in 2017. To the frustration of some investors, the business took several years to ramp up. But sales have substantially grown in recent months. Gilead’s […]

Cell and Gene Therapy, Industry, Mergers and Acquisitions

AstraZeneca Acquires Neogene, Expanding in Cancer Cell Therapy

November 30, 2022

Via: GEN

AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]

Mergers and Acquisitions

J&J to Acquire Momenta Pharmaceuticals for $6.5B

August 19, 2020

Via: Contract Pharma

Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash. This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a […]